MX2019014027A - Uso de glutamina sintetasa para tratar hiperamonemia. - Google Patents

Uso de glutamina sintetasa para tratar hiperamonemia.

Info

Publication number
MX2019014027A
MX2019014027A MX2019014027A MX2019014027A MX2019014027A MX 2019014027 A MX2019014027 A MX 2019014027A MX 2019014027 A MX2019014027 A MX 2019014027A MX 2019014027 A MX2019014027 A MX 2019014027A MX 2019014027 A MX2019014027 A MX 2019014027A
Authority
MX
Mexico
Prior art keywords
glutamine synthetase
relates
hyperammonemia
treating hyperammonemia
protein
Prior art date
Application number
MX2019014027A
Other languages
English (en)
Spanish (es)
Inventor
Tamara Nicolson
Original Assignee
Thoeris Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1708288.4A external-priority patent/GB201708288D0/en
Priority claimed from GBGB1800867.2A external-priority patent/GB201800867D0/en
Application filed by Thoeris Gmbh filed Critical Thoeris Gmbh
Publication of MX2019014027A publication Critical patent/MX2019014027A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/53Ligases (6)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016Disaccharides, e.g. lactose, lactulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K19/00Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93Ligases (6)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y603/00Ligases forming carbon-nitrogen bonds (6.3)
    • C12Y603/01Acid-ammonia (or amine)ligases (amide synthases)(6.3.1)
    • C12Y603/01002Glutamate-ammonia ligase (6.3.1.2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MX2019014027A 2017-05-24 2018-05-24 Uso de glutamina sintetasa para tratar hiperamonemia. MX2019014027A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1708288.4A GB201708288D0 (en) 2017-05-24 2017-05-24 Use of glutamine synthetase for treating hyperammonemia
GBGB1800867.2A GB201800867D0 (en) 2018-01-19 2018-01-19 Use of glutamine synthetase for treating hyperammonemia
PCT/GB2018/051415 WO2018215780A1 (en) 2017-05-24 2018-05-24 Use of glutamine synthetase for treating hyperammonemia

Publications (1)

Publication Number Publication Date
MX2019014027A true MX2019014027A (es) 2020-08-03

Family

ID=62492675

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019014027A MX2019014027A (es) 2017-05-24 2018-05-24 Uso de glutamina sintetasa para tratar hiperamonemia.
MX2024002249A MX2024002249A (es) 2017-05-24 2019-11-22 Uso de glutamina sintetasa para tratar hiperamonemia.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2024002249A MX2024002249A (es) 2017-05-24 2019-11-22 Uso de glutamina sintetasa para tratar hiperamonemia.

Country Status (11)

Country Link
US (4) US12359184B2 (enExample)
EP (3) EP4295904A3 (enExample)
JP (3) JP2020520677A (enExample)
KR (2) KR20250093434A (enExample)
CN (2) CN118105471A (enExample)
AU (2) AU2018272294B2 (enExample)
BR (1) BR112019024750A2 (enExample)
CA (1) CA3064352A1 (enExample)
IL (1) IL270817B2 (enExample)
MX (2) MX2019014027A (enExample)
WO (1) WO2018215780A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4295904A3 (en) * 2017-05-24 2024-02-28 Thoeris GmbH Use of glutamine synthetase for treating hyperammonemia
EP3856231A1 (en) * 2018-09-28 2021-08-04 Thoeris GmbH Use of glutamine synthetase for treating fatty liver disease
CN110133287B (zh) * 2019-05-22 2021-07-30 上海碧云天生物技术有限公司 蛋白抽提溶液及其应用
JP2023532939A (ja) 2020-06-30 2023-08-01 インダストリー-アカデミック コーオペレイション ファウンデーション キョンサン ナショナル ユニバーシティ チロシンを有効成分として含むタンパク質内のチロシンのニトロ化による疾患の予防、改善または治療用組成物
JP2024168541A (ja) 2023-05-24 2024-12-05 トヨタ自動車株式会社 二次電池
CN118949035A (zh) * 2024-07-31 2024-11-15 北京大学第一医院(北京大学第一临床医学院) Glul生物标志物在心力衰竭诊断、治疗或预后预测中的应用

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7590493B2 (en) 2000-07-31 2009-09-15 Ocimum Biosolutions, Inc. Methods for determining hepatotoxins
US6812339B1 (en) 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
US6451547B1 (en) 2001-04-25 2002-09-17 Syn X Pharma Process for differential diagnosis of Alzheimer's dementia and device therefor
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
AUPR805101A0 (en) 2001-10-03 2001-10-25 University Of New South Wales, The A method of genetic screening using an amplifiable gene
JP2003225093A (ja) 2001-11-30 2003-08-12 Sumitomo Pharmaceut Co Ltd 軟骨障害マーカー及びその利用
US6875792B2 (en) 2002-01-31 2005-04-05 Mso Pharma Llc Dosage form of L-Methionine S-Sulfoximine
JP2003274963A (ja) 2002-03-22 2003-09-30 Japan Science & Technology Corp 遺伝子組換え細胞株及びそれを用いた肝機能補助装置
US20050074865A1 (en) 2002-08-27 2005-04-07 Compound Therapeutics, Inc. Adzymes and uses thereof
EP1578996A4 (en) 2002-10-18 2007-12-19 Genentech Inc COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING TUMORS
CA2503390A1 (en) 2002-11-01 2004-05-21 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US20050255114A1 (en) 2003-04-07 2005-11-17 Nuvelo, Inc. Methods and diagnosis for the treatment of preeclampsia
WO2004106489A2 (en) 2003-05-21 2004-12-09 Divergence, Inc Nematode GS-like sequences
WO2005019258A2 (en) 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US20070098702A1 (en) * 2005-02-17 2007-05-03 University Of Maryland, Baltimore Recombinant protein polymer vectors for systemic gene delivery
EP1752143A1 (en) 2005-08-08 2007-02-14 NewThera Novel uses for drugs targeting glutamine synthetase
WO2007071339A1 (en) 2005-12-21 2007-06-28 Universite Catholique De Louvain Isolated liver stem cells
RU2362572C2 (ru) 2007-07-17 2009-07-27 Юрий Георгиевич Каминский Способ снижения концентрации аммиака в крови с помощью аммоцитов и инкапсулированной глутаминсинтетазы
PL3133396T3 (pl) * 2008-04-29 2019-03-29 Horizon Therapeutics, Llc Sposób leczenia z zastosowaniem leków wychwytujących amoniak
JP2012501641A (ja) 2008-09-08 2012-01-26 セレクティス グルタミンシンセターゼ遺伝子からのdna標的配列を切断するメガヌクレアーゼ変異型及びその使用
EP2575862A2 (en) 2010-05-28 2013-04-10 Mind-Nrg Sa Neuregulin isoforms, neuregulin polypeptides and uses thereof
WO2013020914A1 (en) * 2011-08-10 2013-02-14 Celares Gmbh Peg-conjugated peptides
WO2013137583A1 (en) 2012-03-12 2013-09-19 Hanwha Chemical Corporation An expression vector comprising a polynucleotide encoding a modified glutamine synthetase and a method for preparing a target protein employing the same
EP2674495A1 (en) 2012-06-14 2013-12-18 Sanofi CHO expression system
MX377806B (es) 2014-11-07 2025-03-11 Instituto Nac De Ciencias Medicas Y Nutricion Salvador Zubiran Uso de un baculovirus recombinante que media la expresión de la glutamina sintetasa para tratar la encefalopatía hepática.
NZ732632A (en) * 2014-11-24 2021-07-30 Ucl Business Ltd Treatment of diseases associated with hepatic stellate cell activation using ammonia-lowering therapies
EP3307879A2 (en) * 2015-06-10 2018-04-18 Synlogic, Inc. Bacteria engineered to treat diseases associated with hyperammonemia
KR102479894B1 (ko) 2016-03-30 2022-12-21 스파크 테라퓨틱스, 인코포레이티드 재조합 단백질 및/또는 바이러스 벡터 생산용 세포주
EP3452101A2 (en) 2016-05-04 2019-03-13 CureVac AG Rna encoding a therapeutic protein
TWI821905B (zh) 2016-05-11 2023-11-11 美商安美基公司 使用麩醯胺合成酶基因內互補載體直接選擇表現高水準異質蛋白的細胞
CN110023500B (zh) 2016-11-16 2024-10-11 新加坡科技研究局 作为选择标记的减毒谷氨酰胺合成酶
EP4295904A3 (en) 2017-05-24 2024-02-28 Thoeris GmbH Use of glutamine synthetase for treating hyperammonemia
US11479792B2 (en) 2017-07-13 2022-10-25 Upside Foods, Inc. Compositions and methods for increasing the efficiency of cell cultures used for food production
US11713468B2 (en) 2017-08-02 2023-08-01 Dna Twopointo Inc. DNA vectors and elements for sustained gene expression in eukaryotic cells
CN109988777A (zh) 2017-12-29 2019-07-09 南京金斯瑞生物科技有限公司 谷氨酰胺合成酶基因以及应用
CN110714057A (zh) 2018-07-11 2020-01-21 成都金洛克生物技术有限公司 用于检测外源基因整合和定位的通用型fish探针及其应用
CN109504709B (zh) 2018-11-28 2020-07-24 上海安民生物技术有限公司 白蛋白启动子驱动的白蛋白表达载体
AU2020225647B2 (en) 2019-02-22 2025-06-05 Smith & Nephew Asia Pacific Pte Limited Combination electrosurgical and mechanical resection device
WO2020227206A1 (en) 2019-05-07 2020-11-12 Amgen Inc. Vectors and expression systems for producing recombinant proteins

Also Published As

Publication number Publication date
BR112019024750A2 (pt) 2020-06-09
US11932885B2 (en) 2024-03-19
CN118105471A (zh) 2024-05-31
KR20200018488A (ko) 2020-02-19
WO2018215780A1 (en) 2018-11-29
IL270817B2 (en) 2025-10-01
US20240150746A1 (en) 2024-05-09
AU2018272294B2 (en) 2024-05-23
JP7688926B2 (ja) 2025-06-05
EP3630077A1 (en) 2020-04-08
JP2023085301A (ja) 2023-06-20
AU2024201089A1 (en) 2024-03-14
US20210145946A1 (en) 2021-05-20
EP4295904A3 (en) 2024-02-28
AU2018272294A1 (en) 2020-01-16
CA3064352A1 (en) 2018-11-29
MX2024002249A (es) 2024-03-05
IL270817B1 (en) 2025-06-01
US20220401532A1 (en) 2022-12-22
IL270817A (en) 2020-01-30
JP2024059833A (ja) 2024-05-01
CN111093641A (zh) 2020-05-01
KR20250093434A (ko) 2025-06-24
AU2024201089B2 (en) 2025-04-24
EP4295904A2 (en) 2023-12-27
EP4119133A1 (en) 2023-01-18
US12338471B2 (en) 2025-06-24
JP2020520677A (ja) 2020-07-16
US20220401531A1 (en) 2022-12-22
US12359184B2 (en) 2025-07-15

Similar Documents

Publication Publication Date Title
MX2024002249A (es) Uso de glutamina sintetasa para tratar hiperamonemia.
MX2019005379A (es) Derivado de pirazolo-heteroarilo, metodo de preparacion y uso medico del mismo.
MX387788B (es) Uso de agentes activos durante tratamientos quimicos.
MX389700B (es) Derivados de pirazolopiridina como moduladores de cinasa 1 progenitora hematopoyetica (hpk1) y usos de los mismos para tratamiento de cancer.
MX2016008201A (es) Tratamiento del cancer usando combinaciones de inhibidores de erk y raf.
MX2018013240A (es) Composiciones antiirritantes sinergisticas de taurina y aloe.
CL2020000220A1 (es) Composiciones que comprenden aminoácidos para su uso en el tratamiento de enfermedades relacionadas con la disfunción mitocondrial.
CL2017002636A1 (es) Composiciones que comprenden una combinación de un anticuerpo anti muerte programada 1 (pd-1) y otro anticuerpo.
CL2017001488A1 (es) Benzamidas sustituidas con 1,3–tiazol–2–ilo
MX392977B (es) Composiciones y metodos para programar celulas terapeuticas utilizando nanoportadores de acidos nucleicos dirigidos.
NZ742208A (en) Topical pharmaceutical formulations for treating inflammatory-related conditions
MX370664B (es) Inhibidores de la proteína regulada por glucosa 94 (gpr94) selectivos y usos de los mismos.
MX2022014313A (es) Formulaciones para administracion oral de agentes activos con perfil de absorcion controlada.
SV2016005320A (es) Formulaciones y mã‰todos de tratamiento con queratina
UY37952A (es) Formulaciones de un inhibidor de la quinasa trk macrocíclica
GT201400043A (es) Imidazopiridazinas sustituidas con amino
CL2015002433A1 (es) Imidazopiridazinas sustituidas
EA201991447A1 (ru) Снижение вязкости фармацевтических составов
MX2017007256A (es) Inhibidor de bromodominio como adyuvante en la inmunoterapia contra el cancer.
GB2541835A (en) Multivesicular liposome formulations of tranexamic acid
CR20180228A (es) Terapia adjunta con 25-hidroxi vitamina d y articulos de la misma
MX2019008999A (es) Composicion inyectable para prevenir la perdida del pelo o estimular el crecimiento del pelo.
MX2018011536A (es) Composiciones y métodos para el uso de eflornitina, y derivados y análogos de la misma para tratar cánceres, incluyendo gliomas.
SV2017005466A (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
CL2020000221A1 (es) Composiciones que comprenden aminoácidos para su uso en el tratamiento de enfermedades relacionadas con la disfunción mitocondrial.